Company ProfilePremium

Invex Therapeutics Ltd

Company Profile Analysis

Ticker: IXC.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Invex Therapeutics Ltd - Company showcase

Year Founded & Workforce

2019

100 Employees

Invex Therapeutics Ltd logo

Invex Therapeutics Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Invex Therapeutics Ltd Overview

Invex Therapeutics is a Perth-based, ASX-listed micro-cap biopharmaceutical company built around the repurposing of Exenatide — an already-approved GLP-1 receptor agonist — to treat neurological disorders associated with raised intracranial pressure (ICP). Its sustained-release formulation, trademarked Presendin™, reached a registration-directed Phase III trial in idiopathic intracranial hypertension (IIH EVOLVE) before the Board terminated the study in August 2023, concluding that the rise of cheaper, more weight-reducing GLP-1 drugs such as semaglutide would make an orphan-priced Presendin uneconomic in IIH. The company subsequently returned A$14.0m to shareholders, dismantled its UK clinical operation, and reverted to a preclinical, virtual model. Its residual value now rests on (i) patents and orphan drug designations covering GLP-1RAs for raised ICP, (ii) preclinical Alzheimer's disease data generated with Tessara Therapeutics, and (iii) a clean, debt-free balance sheet with roughly A$4m of cash that positions it as a potential vehicle for an asset acquisition or reverse transaction.


Company's own description (FY2026 Annual Report, Directors' Report)

The FY2026 Annual Report describes Invex as a biopharmaceutical group focused on repurposing an approved drug, Exenatide, for the treatment of neurological conditions derived from or involving raised intracranial pressure. It identifies the principal activity during FY2026 as the development of Exenatide, including the generation of new preclinical data in Alzheimer's disease (AD) under a collaboration with Tessara Therapeutics, and notes that the Board held discussions with several third parties owning complementary assets that could create additional value for shareholders. The FY2024 report extended the stated scope to traumatic brain injury (TBI), stroke and hydrocephalus, and to early-stage data in glaucoma (via lowering of intraocular pressure).

Independent characterisation

In practice, Invex today is best characterised as a cash-backed, intellectual-property holding company with a low-cost preclinical research option. It has:

  • No revenue-generating products, services, subscriptions or licences. All income since listing has been "other income" — interest on cash deposits and R&D tax incentive rebates (Australian and UK).

No clinical-stage program: The only clinical asset (Presendin in IIH) was terminated in FY2024; the related manufacturing relationship with Peptron, Inc. was mutually terminated on 22 December 2023, with Peptron receiving an exclusive royalty-free licence to commercialise Presendin for IIH in Korea and China and a first right of refusal over global IIH development rights.

A virtual operating model: Research is conducted by contract research partner Tessara Therapeutics (ADBrain™ human 3D neural microtissue model). Administration is outsourced to company secretarial/accounting providers.

A stated corporate-development mandate: Since FY2024 the Board has repeatedly said it is assessing complementary neurological assets and, per a BIO International Convention partnering profile, has also been seeking partners to acquire its core raised-ICP IP for cash, equity or a combination.

Business model and revenue model

DimensionAssessment
Business modelDrug repurposing / specialty biotech; historically "develop to Phase III then partner or commercialise" in an orphan indication; now preclinical research plus corporate development
Revenue mix (product / service / subscription / licensing)0% / 0% / 0% / 0%. No operating revenue in any year FY2022–FY2026
Other income sourcesInterest income; R&D tax incentive rebates (Australia; UK until FY2025); minor "other revenue" (A$16,917 in FY2026)
Value chain positionEarly-stage R&D and IP owner; no manufacturing, distribution or sales capability. Drug substance previously sourced from Peptron (Korea)
Intended customers (if commercialised)Neurologists, neuro-ophthalmologists and neurosurgical/ICU teams treating raised-ICP conditions; payers and health systems in EU/UK/US/Australia
End-markets targetedIIH (orphan), moderate-to-severe TBI (orphan in EU), hydrocephalus/NPH and meningitis (patent claims), glaucoma (early data), Alzheimer's disease (preclinical)

Strategy

Stated strategy themes (FY2024–FY2026 Annual Reports and quarterlies)

  1. Generate new preclinical data for Exenatide in CNS indications, presently Alzheimer's disease, to build an evidence base for partnering — the FY2026 report states that the expanded Tessara program is intended to strengthen understanding of Exenatide's mechanistic profile and support engagement with prospective development and commercialisation partners.

  2. Maintain and extend IP and regulatory designations (renewed EU TBI ODD in FY2026; patents in US/EU).

  3. Pursue complementary neurological assets via acquisition or in-licensing, preferably in neuroscience or orphan disease (discussions with "a number of potential third parties" referenced in FY2026).

  4. Divest core raised-ICP GLP-1RA IP for cash, equity or both (BIO partnering profile; roic.ai summary of 2025 disclosures).

  5. Cost discipline — minimal overhead, outsourced administration, no employees.

Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDescriptionStatus
Tessara collaboration (phase 1)15 Aug 2024Exenatide tested in ADBrain™ AD model; showed improved neuronal survivalCompleted
Tessara collaboration expansionMar 2025Neuroinflammation, glucose metabolism, neural network and AD biomarker analysesResults reported in FY2026 (Nf-L −40%, IL-6/IL-8 reductions)
Acquisition of rare neurological disease company (Fragile X focus)Exclusive negotiations to 29 Sep 2025Would have diversified pipeline into rare neurodevelopmental disordersTerminated 30 Sep 2025
EU TBI orphan designation renewalH1 FY2026Maintains EU orphan pathwayCompleted
UK subsidiary wind-upFeb 2026Simplified structureCompleted
Expanded Tessara program24 Apr 2026Head-to-head Exenatide vs dulaglutide; combinations with approved AD symptomatic drugs; combinations with naturally occurring synergistic factors; cytotoxicity, viability and ferroptosis assaysIn progress (A$379k R&D outflow in Q4 FY2026)
Treasury: term depositsFY2026A$2.5m placed on term depositOngoing

ESG commitments, cost programs and guidance

No sustainability or ESG commitments have been announced. No formal cost-reduction program with numeric targets has been published, though overhead reduction is evident. Management has issued no financial guidance or medium-term targets. The FY2026 Directors' Report states there are no likely developments not already disclosed.

Products & Services

Invex has no marketed products or services. Its "portfolio" consists of one molecule (Exenatide) across several indications, plus IP and regulatory designations.

Presendin™ (sustained-release Exenatide) — lead asset

AttributeDetail
DescriptionOnce-weekly, subcutaneous, sustained-release Exenatide microsphere formulation originally developed by Peptron, Inc. (KOSDAQ: 087010); Presendin™ is Invex's granted trademark
MechanismGLP-1 receptor agonism; preclinical work by Prof Sinclair identified GLP-1RAs as reducing cerebrospinal fluid secretion and brain pressure
Development statusIIH: Phase III terminated (Aug 2023). Other indications: preclinical
Target customerNeurology/neuro-ophthalmology (IIH), neurocritical care (TBI)
Launch yearNot launched
Pricing modelNot applicable; the company's own analysis concluded orphan-premium pricing was not achievable given GLP-1RA price points
Out-licenceExclusive royalty-free licence to Peptron for IIH in Korea and China (Dec 2023); Peptron holds a first right of refusal over global IIH development rights

Indication-by-indication catalog

ProgramStageKey data / statusRegulatory/IP support
Idiopathic Intracranial Hypertension (IIH)Phase III terminated (IIH EVOLVE, NCT05347147)Phase II "IIH Pressure" trial (reported May 2020; published in Brain) showed ICP reduction; Phase III enrolled 13 patients before closureEMA and FDA orphan drug designations (IIH); paediatric investigation plan approved by EMA PDCO
Moderate-to-severe Traumatic Brain Injury (TBI)PreclinicalNo clinical data; proof-of-concept trial was "under consideration" in FY2023 but never initiatedEMA ODD granted 23 Jun 2023 and renewed in FY2026; US ODD filed late FY2023 — grant status not publicly disclosed; US Patent 11,738,067 includes brain injury/trauma claims
Hydrocephalus / normal pressure hydrocephalus / meningitisPreclinical (IP-led)No disclosed clinical dataEP4000630 (Decision to Grant, 22 Nov 2023)
Acute strokePreclinical / conceptualNamed in early prospectus-era descriptions; no disclosed program activity since FY2024Covered by raised-ICP patent family
GlaucomaEarly preclinicalEarly-stage data on lowering intraocular pressure referenced in FY2024 report; no further updates—
Alzheimer's disease (AD)Preclinical (in vitro, human 3D microtissue)In Tessara ADBrain™: ~40% reduction in secreted neurofilament light chain; reductions in IL-6 and IL-8; possible effect on amyloid-beta (confounded by GAPDH change); no effect on phosphorylated Tau or insulin-dependent glucose uptakePotential new IP flagged in 2025; no grant disclosed

Flagship "offering" summary

The only named flagship is Presendin™. There are no product versions, pricing schedules or commercial SKUs.

Financial Narrative

All tables: AUD thousands unless noted; FY = year ended 30 June. Sources: FY2023 Annual Report (FY2022–FY2023 data), FY2024 Annual Report (FY2024), FY2026 Annual Report (FY2025–FY2026). Figures rounded to nearest A$1,000.

Income statement

Notes and definitions. EBITDA is computed as pre-tax loss less interest income; the group has no depreciation, amortisation or interest expense. Gross, operating, EBITDA and net margins are not meaningful because operating revenue is nil in every year; revenue CAGR is likewise not meaningful. The FY2026 Appendix 4E reports "Net Tangible asset per share" of 1.80 cents for FY2026 and 0.63 cents for FY2025 — these figures equal the loss per share and appear to be a labelling error; computed NTA per share is approximately 5.20 cents (FY2026) and 6.98 cents (FY2025). The FY2023 4E similarly shows NTA of 0.28/0.38, inconsistent with the balance sheet. A minor discrepancy also exists in the FY2026 tax note, which cites a pre-tax loss of A$1,332,352 versus A$1,352,352 in the income statement.

Commentary. The P&L trajectory maps directly to the clinical program lifecycle. FY2023 was peak spend (A$7.40m R&D) as IIH EVOLVE commenced, with Phase III trial costs of A$3.85m and drug manufacturing of A$0.74m. FY2024 R&D fell 72% to A$2.04m as the trial was wound down, and the net loss fell 79% to A$1.64m, cushioned by a A$1.21m UK R&D rebate. FY2025 was the cost trough: net loss of only A$0.48m, with R&D of A$0.20m and admin of A$0.72m. FY2026 marks an inflection back upward — net loss rose 184% to A$1.35m, driven by (i) Tessara-related consultant costs (R&D consultants A$0.44m vs A$0.14m) and (ii) a governance contest: legal fees jumped to A$0.21m (FY2025: A$4k), audit/corporate advice/tax fees doubled to A$0.14m, NED fees more than doubled to A$0.13m, and A$75k of transaction costs were incurred on the aborted acquisition. Simultaneously, interest income fell 45% as cash declined and the R&D rebate stream largely ended with the UK subsidiary's closure.

R&D expense detail

FY2026 Phase III trial cost was A$443 (rounds to zero).

Administration expense detail

FY2025 admin also included A$38k of UK director fees (FY2026: A$3k).

Balance sheet

Commentary. The balance sheet is entirely current: no PP&E, no capitalised development, no intangibles (all R&D is expensed per policy), no leases and no debt. Equity fell 86% between FY2022 and FY2026, of which A$14.0m was the FY2024 capital return and the remainder cumulative losses. The FY2026 shift of A$2.5m into term deposits (A$500k of cash also on fixed term) is a treasury decision, not a change in liquidity. Unrecognised deferred tax assets of A$2.82m at FY2026 (Australian tax losses A$2.74m tax-effected) represent an under-appreciated asset for a potential acquirer or reverse-takeover vehicle, subject to continuity-of-ownership/business tests. Foreign tax losses (A$1.13m tax-effected at FY2024) were effectively lost with the UK subsidiary's dissolution.

Cash flow

Quarterly granularity, FY2026 (Appendix 4C): Q3 FY2026 operating outflow approximately A$79k (R&D A$53k; admin A$67k vs A$444k in Q2 FY2026, the Q2 spike reflecting s249D meeting costs and termination payments to departing directors and the company secretary); Q4 FY2026 operating outflow A$501k (R&D A$379k for the expanded Tessara program; admin A$135k; related-party payments A$54k). Cash and equivalents per Q3 4C: A$4.517m; per Q4 4C: A$4.016m.

Runway: At the FY2026 operating burn of A$1.36m, cash and deposits of A$4.02m represent roughly 3.0 years of funding; at the Q4 FY2026 quarterly rate of A$0.50m, roughly 8 quarters. A transaction or expanded program would shorten this materially.

Ratios

ROE and ROA match Market Index's published FY2024 (-28.86%, -26.83%) and FY2025 (-9.09%, -8.72%) figures. ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful (no revenue, no debt, no interest expense, no inventory). FY2022 opening-cash figure for the burn ratio uses 30 June 2021 cash of A$32.716m.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts/services

Research & Development (Australia)

All activities: Exenatide/Presendin IP, preclinical research (Tessara collaboration), patent prosecution, corporate administration

Presendin™ (sustained-release Exenatide) — no commercial products

Results by Segment and Revenue by Segment (%)

MetricFY2022FY2023FY2024FY2025FY2026

R&D segment operating revenue (AUD K)

00000

R&D segment other income (AUD K)

2621,2561,704462192

R&D segment pre-tax result (AUD K)

-3,953-7,750-1,642-477-1,352

Contribution to group revenue (%)

100100100100100

Group Entities

EntityJurisdictionOwnership FY2025Ownership FY2026Role

Invex Therapeutics Ltd

Australia

Parent

Parent

Listed parent, IP holder

Invex Therapeutics Ltd (UK)

United Kingdom

100%

0% (dissolved 24 Feb 2026)

Former employer of UK clinical team; claimant of UK R&D tax credits

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Operating revenue (AUD K)

00000

Other income total (AUD K)

2621,2561,704462192

Interest income (AUD K)

80797492232128

R&D tax rebate income (AUD K)

1824591,21222947

Other revenue (AUD K)

000017

Gross profit (AUD K)

00000

R&D expense (AUD K)

2,9637,4002,039204520

Finance, compliance and admin expense (AUD K)

9001,1251,1707181,024

Share-based payment expense (AUD K)

352481138160

Total operating expenses (AUD K)

4,2159,0063,3469381,544

Operating income before other income (AUD K)

-4,215-9,006-3,346-938-1,544

EBITDA excl. interest income (AUD K)

-4,033-8,547-2,134-709-1,481

Pre-tax income (AUD K)

-3,953-7,750-1,642-477-1,352

Income tax (AUD K)

00000

Net income (AUD K)

-3,953-7,750-1,642-477-1,352

Total comprehensive income (AUD K)

-3,950-7,732-1,679-457-1,352

EPS basic (AUD cents)

-5.26-10.31-2.18-0.63-1.80

EPS diluted (AUD cents)

-5.26-10.31-2.18-0.63-1.80

Dividends per share (AUD cents)

00000

Capital return per share (AUD cents)

0018.6300

Key Financials

MetricFY2022FY2023FY2024FY2025FY2026

Phase III clinical trial (AUD K)

7623,8471,081300

Manufacturing (Peptron drug and placebo) (AUD K)

326744000

Consultants (AUD K)

7151,789285137441

Employee costs (AUD K)

51029321000

COO costs (AUD K)

031227400

CSO executive director fees (AUD K)

3152998800

Patent expenses (AUD K)

143117733775

Regulatory advice and other R&D (AUD K)

19102700

Total R&D (AUD K)

2,9637,4002,039204520

Key Financials — Executive director fees

MetricFY2022FY2023FY2024FY2025FY2026

Executive director fees (AUD K)

13918034017294

Non-executive director fees (AUD K)

16016015060131

Accounting and company secretarial (AUD K)

132148291154141

Legal fees (AUD K)

10931304209

Audit, corporate advice and tax (AUD K)

68618464142

Insurance (AUD K)

92177957266

Investor relations and PR (AUD K)

51112152428

Travel and entertainment (AUD K)

31103596017

Transaction costs (AUD K)

000075

Total admin (AUD K)

9001,1251,1707181,024

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Cash and cash equivalents (AUD K)

29,33922,4706,0255,3751,516

Short-term term deposits (AUD K)

00002,500

Cash plus term deposits (AUD K)

29,33922,4706,0255,3754,016

Other receivables (AUD K)

146334959347

Total assets (AUD K)

29,48522,8046,1205,4684,064

Goodwill and intangibles (AUD K)

00000

Trade and other payables (AUD K)

1,0041,572432221153

Short-term debt (AUD K)

00000

Long-term debt (AUD K)

00000

Net debt (AUD K)

-29,339-22,470-6,025-5,375-4,016

Total liabilities (AUD K)

1,0041,572432221153

Contributed equity (AUD K)

36,41336,41322,41222,41222,412

Reserves (AUD K)

1,8972,3972,4972,5332,533

Accumulated losses (AUD K)

-9,829-17,579-19,221-19,698-21,035

Total equity (AUD K)

28,48121,2315,6885,2473,910

Working capital (AUD K)

28,48121,2315,6885,2473,910

Book value per share (AUD cents)

37.9028.257.576.985.20

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Payments to suppliers and employees (AUD K)

-3,639-8,125-4,148-1,114-1,535

R&D tax rebate received (AUD K)

1824591,21222949

Interest received (AUD K)

80797492232129

Operating cash flow (AUD K)

-3,377-6,869-2,444-653-1,359

Capex (AUD K)

00000

Free cash flow (AUD K)

-3,377-6,869-2,444-653-1,359

Investing cash flow incl. term deposits (AUD K)

0000-2,500

Capital return paid (AUD K)

00-14,00100

Dividends paid (AUD K)

00000

Share buybacks (AUD K)

00000

Equity raised (AUD K)

00000

Net change in cash (AUD K)

-3,377-6,869-16,445-653-3,859

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE year-end equity basis (%)

-13.9-36.5-28.9-9.1-34.6

ROA year-end assets basis (%)

-13.4-34.0-26.8-8.7-33.3

Current ratio (x)

29.414.514.224.826.5

Debt to equity (x)

00000

Cash per share (AUD cents)

39.0429.908.027.155.34

Operating cash burn as % of opening cash (%)

10.323.410.910.825.3

Revenue by Region

MetricFY2024FY2025FY2026

Australia operating revenue (AUD K)

000

United Kingdom operating revenue (AUD K)

000

Rest of world operating revenue (AUD K)

000

UK R&D tax rebate cash received (AUD K)

1,2122290

Share Count (millions) and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Shares on issue (millions)

75.1575.1575.1575.1575.15

Book value per share (AUD cents)

37.9028.257.576.985.20

Cash and deposits per share (AUD cents)

39.0429.908.027.155.34

Dividends per share (AUD cents)

00000

Capital return per share (AUD cents)

0018.6300

Share Price and Market Valuation

MetricFY2024FY2025FY2026

Year-end share price (AUD)

0.060.090.09

Year-end market cap (AUD Mn)

4.56.86.8

Price to book (x)

0.791.291.73

Share Price & Returns

ReferencePrice / data

IPO price (Jul 2019)

A$0.40

Placement price (May 2020)

A$1.30

Capital return (Dec 2023)

A$0.1863 per share returned

52-week range (as of early 2026, Yahoo)

A$0.059 – A$0.18

52-week range (Stocklight, Jul 2026)

A$0.075 – A$0.18

Latest verified trading (23–24 Jul 2026)

A$0.115–0.12; market cap ≈ A$8–9m

Total shareholder return FY2024 / FY2025 (Market Index)

-70.0% / +48.4%

Beta (5Y monthly, Yahoo)

0.22

Valuation Snapshot

MultipleValueComment

P/E

n/m

Loss-making

EV

≈ A$4.3m

Market cap less A$4.0m cash/deposits

EV/EBITDA

n/m

Negative EBITDA

EV/Sales

n/m

Nil revenue

P/B

≈ 2.1x

vs equity A$3.91m

Market cap / cash

≈ 2.1x

Market ascribes ~A$4m to IP, listing and tax attributes

Capital Markets

ItemStatus

Analyst consensus

None — not covered by major brokers (Market Index)

Dividend policy

Directors do not propose dividends; none ever paid

Buyback authorisation

None (no on-market buyback program)

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity profile

No debt

Options overhang

1.11m options at A$0.67 expiring 1 Dec 2026 — deeply out of the money (≈1.5% of issued capital)

Exercise price note

Options were originally struck at A$0.87 (FY2023 AR) and are shown at A$0.67 from FY2024, consistent with a capital-return adjustment of ≈A$0.19

Analyst Conclusions

Management guidance

None. The Board indicates continued review of investment opportunities and progression of the expanded Tessara AD program, with no likely developments disclosed beyond these.

Consensus growth expectations

None (no analyst coverage).

Bull case

  1. Shell value with a floor: cash and deposits of A$4.02m (5.34c/share) against a share price around 11c means the market is paying only ~A$4m for listing status, ~900-holder register, patents, ODDs and A$2.7m of tax-effected losses — a modest premium for a transaction-ready vehicle.

  2. Board built for a deal: the November 2025 board (a corporate lawyer, a former Big-4/McKinsey healthcare M&A adviser and a serial Perth small-cap chairman), installed with substantial-holder support, appears designed to execute an asset injection or reverse takeover that the prior board's Fragile X deal attempted.

  3. Optionality in IP: granted US/EU use patents, the EU TBI orphan pathway and Peptron's ROFR over global IIH rights provide multiple potential monetisation routes for cash or equity.

Bear case

  1. Value leakage: cash fell A$1.36m in FY2026, including over A$0.3m of contest-related legal, advisory and termination costs; without a deal, the floor erodes by ~A$1–2m per year.

  2. Scientific thesis impaired: the company's own market assessment rendered Presendin uneconomic in IIH, and large GLP-1 neuro trials (Exenatide in Parkinson's, semaglutide in AD) have reported negative results, leaving in vitro ADBrain™ data with limited partnering currency.

  3. No people, no alignment: no executives, nil director shareholdings, a concentrated register and a history of abrupt board turnover create execution and governance risk; any transaction will likely involve heavy dilution at prices near or below cash backing.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
Q1 FY2027 Appendix 4CBy 31 Oct 2026Burn rate under expanded Tessara program
2026 AGMLikely Nov–Dec 2026Board re-election, incentive plan, any strategic resolutions
Expiry of 1.11m options1 Dec 2026Removes overhang
Tessara expanded program resultsLate CY2026 – 1H CY2027 (inferred)Determines whether AD data supports partnering
Announcement of acquisition, RTO or IP saleUnscheduledPrimary value driver
Substantial holder notices (Tattarang, Peterson/Celtic)OngoingSignals of control intentions
H1 FY2027 Appendix 4DFeb 2027Cash position and cost discipline
ASX compliance postureOngoingRisk of queries on adequacy of operations

Concluding analyst verdict

Invex Therapeutics is no longer an operating drug developer in any meaningful sense; it is a lightly resourced listed vehicle holding cash, a niche IP estate and a small preclinical research option. The pivotal strategic decision — terminating the IIH EVOLVE Phase III in August 2023 — was arguably correct: the company's own market assessment showed that the weight-loss superiority and price trajectory of semaglutide-class drugs would undermine an orphan-priced, weaker-weight-loss Exenatide formulation in a disease whose primary management principle is weight reduction. Returning A$14.0m to shareholders rather than pursuing a speculative pivot was shareholder-friendly. Since then, however, the residual company has struggled to create value. Losses re-accelerated in FY2026 to A$1.35m, a third of which is attributable to a boardroom contest that also killed a potential pipeline-diversifying acquisition. The Alzheimer's program, while scientifically interesting (a ~40% reduction in neurofilament light chain and lower IL-6/IL-8 in human microtissues), is in vitro, mechanistically inconsistent on Tau and amyloid, and arrives after negative large-scale GLP-1 neurodegeneration readouts, which limits its partnering value.

The investment case therefore reduces to a transaction call. At roughly 11c per share against 5.3c of cash per share, the market prices about A$4m of option value on the new board's ability to execute an asset injection, reverse takeover or IP sale on terms that do not destroy the cash floor. The concentrated, family-office-dominated register (Tattarang 11.77%; Peterson/Celtic-associated interests) makes such a transaction feasible but also means minority holders' outcomes will be shaped by a few holders' agendas. For institutional purposes, Invex is uninvestable on fundamentals and suitable only as a special-situation shell exposure. Rating framework (analyst, not a recommendation): speculative / event-driven. Key test: whether a value-accretive transaction is announced before cash and deposits fall below roughly A$3m.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackground

Mr David Wheeler FAICD

Non-Executive Chairman

Director since 8 Nov 2023; Chairman following Nov 2025 board reconstitution

30+ years of senior executive, directorship and corporate advisory experience; founding Director and Partner of Pathways Corporate (Perth boutique corporate advisory). Current: Chair of OZZ Resources, Avira Resources, Yugo Metals; NED of Ragnar Metals, MOAB, Cycliq Group, Earth Energy

Mr Simon Owen

Non-Executive Director

10 Nov 2025

35+ years as corporate and commercial lawyer and corporate adviser, with focus on developing businesses, innovation, IP and capital markets; prior chair/director roles in listed and unlisted companies

Prof Warren Harding AM

Non-Executive Director

10 Nov 2025

30+ years across global healthcare, biotech and medtech; former Managing Partner at Accenture, Deloitte and PwC; Senior Adviser to McKinsey & Co; Board director of the Australian Digital Health Agency; former member of WA Disability Services Commission (2020–24); co-founder/director of two emerging medtech companies

Mr Tim Slate CA

Company Secretary

10 Nov 2025 (joint; sole since 23 Mar 2026)

15+ years in accounting and company secretarial roles; B.Com (UWA), Chartered Accountant, AGIA, GAICD

Directors' Remuneration

NameCash fees (AUD)Termination benefit (AUD)Share-based (AUD)Total (AUD)

David Wheeler

47,5000047,500

Simon Owen

39,8000039,800

Warren Harding

30,8000030,800

David McAuliffe (to 7 Nov 2025)

12,5000012,500

Dr Thomas Duthy (to 7 Nov 2025)

71,66522,291093,956

Total KMP

202,26522,2910224,556

Directors' Remuneration (Annual)

MetricFY2022FY2023FY2024FY2025FY2026

Total KMP remuneration (AUD K)

1,2481,7471,284341225

KMP share-based payments (AUD K)

281462130130

Governance Overview

AttributeStatus

Board size

3 (all non-executive)

Independence

Not formally classified in the FY2026 AR; on the face of disclosures, all three are non-executive with nil shareholdings. Wheeler's Pathways Corporate advisory role and the circumstances of the November 2025 appointments (following a substantial shareholder's requisition) should be considered when assessing independence

Chair/CEO separation

No CEO; Chair is non-executive

Gender diversity

0% female directors (FY2023: 40% female board representation)

Board meetings FY2026

5 (Wheeler 5/5; Owen 2/2; Harding 2/2; Duthy 3/3; McAuliffe 3/3)

Say-on-pay

82.87% support at 2025 AGM (held 17 Feb 2026); 97.5% at 2023 AGM

Board & Management Changes

DateChangeContext

10 Jul 2023

Dr Jason Loveridge (Chair) and Prof Alexandra Sinclair (ED/CSO) resign

Major shareholders withdrew support after 28 Jun 2023 trial update

8 Nov 2023

David Wheeler appointed NED

Post-trial-closure board refresh

1 Feb 2024

COO Carol Parish employment terminated (A$82k redundancy)

UK team redundancies

30 Jun 2024

Dr Megan Baldwin retires

Board downsizing

Sep–Oct 2025

Celtic Capital Pte Ltd (substantial holder) requisitions meeting to remove Chair McAuliffe and ED Duthy; Board (other than Wheeler) recommended against

Governance contest; exclusivity on acquisition target ended

7 Nov 2025

Duthy, McAuliffe and Company Secretary/CFO Narelle Warren resign; requisitioned meeting cancelled

Contest resolved in requisitioner's favour without a vote

10 Nov 2025

Simon Owen and Prof Warren Harding AM appointed; Tim Slate and Carla Healy appointed joint Company Secretaries

New board installed

23 Mar 2026

Carla Healy resigns as joint Company Secretary

Tim Slate remains

Major Shareholders

RankHolderShares%
1

Tattarang (Forrest family private investment group)

8,846,15411.77
2

Peterson

5,600,0007.45
3

Tisia Nominees Pty Ltd (Henderson Family A/C)

3,725,0004.96
4

Mr Jason Loveridge (co-founder)

3,374,4624.49
5

Mr David Jerimiah McAuliffe (former Chair)

2,850,0013.79
6

JK Nominees Pty Ltd (The JK Fund A/C)

2,750,0003.66
7

Dr Paul Francis Worth

2,500,0003.33
8

Celtic Finance Corp Pty Ltd

2,390,0003.18
9

Mrs Kathryn Salkilld

2,293,0003.05
10

Porjed Pty Ltd (Deporj A/C)

2,239,8172.98

11–20

Bannaby Investments, Warragoon Investments, Rock the Polo, Anthony Grist, Andrew Clayton, Zerrin Investments, Hammerhead Holdings, Chelsea Investments (WA), Okanagan Trading, De Nicola Family S/F

11,538,51815.35
—

Top 20 total

48,106,95264.01

Competitive Landscape

Competitors by Segment

IndicationCompetitor / alternativeTypeRelative positioning

IIH

Novo Nordisk — semaglutide (Ozempic/Wegovy/Rybelsus)

Approved GLP-1RA for obesity/diabetes, used off-label to drive weight loss

Decisive: the reason Invex terminated EVOLVE (superior weight loss, scale pricing)

IIH

Eli Lilly — tirzepatide (Mounjaro/Zepbound)

Approved GIP/GLP-1 agonist

Further raises the bar for weight-loss-driven IIH management

IIH

Generic acetazolamide and topiramate

Off-label standard of care

Cheap incumbents; no approved IIH-specific therapy per Invex disclosures

IIH

Bariatric surgery, CSF shunting, venous sinus stenting, optic nerve sheath fenestration

Surgical/device

Established for refractory cases

IIH

AstraZeneca / University of Birmingham — 11β-HSD1 inhibitor (AZD4017) research

Investigational

—

TBI / raised ICP

Hyperosmolar therapy (mannitol, hypertonic saline), decompressive craniectomy, CSF drainage

Standard of care

No EMA/FDA-approved drug specifically for intracranial hypertension in TBI per Invex

Alzheimer's disease

Eli Lilly — donanemab (Kisunla); Eisai/Biogen — lecanemab (Leqembi)

Approved anti-amyloid antibodies

Dominant disease-modifying class

Alzheimer's disease

Novo Nordisk — semaglutide (evoke program)

GLP-1RA in AD

Large-pharma GLP-1 AD test; reported negative (see 13.3)

Alzheimer's (ASX peers)

Actinogen Medical (ASX: ACW), Alterity Therapeutics (ASX: ATH), Neurotech International (ASX: NTI)

ASX-listed CNS biotechs

Clinical-stage peers competing for the same small-cap investor capital

Exenatide supply

AstraZeneca (Byetta/Bydureon originator)

Originator of Exenatide

Controls the reference product; generic/biosimilar context relevant to pricing

Peer Comparison FY2026

AttributeInvex (FY2026)Novo NordiskEli LillyASX CNS micro/small-cap peers

Operating revenue

Nil

Tens of billions (USD equivalent)

Tens of billions (USD)

Generally nil/minimal

Development stage

Preclinical

Commercial

Commercial

Phase 1–3

R&D spend

A$0.52m

Billions

Billions

Several A$m to tens of A$m

Revenue growth

n/m

Not compiled here

Not compiled here

Not compiled here

Margins

n/m

Not compiled here

Not compiled here

n/m

Recent Developments

There have been no product launches, contract wins, guidance revisions, layoffs (no staff), or regulatory actions in the period.

Company Snapshot

100

Employees

2019

Founded

Perth, Australia

Headquarters

SWOT Analysis

Strengths

  • Clean balance sheet: A$4.02m cash and term deposits vs A$0.15m total liabilities and zero debt at 30 June 2026 (FY2026 AR).
  • Granted IP: US Patent 11,738,067 (Aug 2023) and EP4000630 (Nov 2023) covering GLP-1RAs in raised-ICP conditions (FY2024 AR).
  • Orphan designations maintained: EU TBI ODD renewed in FY2026; EU and US IIH ODDs (FY2026 AR).
  • Human proof-of-mechanism: Phase II IIH Pressure trial published in Brain (FY2023 AR), showing ICP reduction.
  • Very low fixed cost base: FY2025 operating burn of only A$0.65m; no employees or leases (FY2026 AR).
  • Unrecognised tax assets: A$2.82m of net deferred tax assets not brought to account, including A$2.74m relating to Australian tax losses (FY2026 AR Note 6).

Weaknesses

  • No clinical program since EVOLVE termination on 21 Aug 2023 (FY2024 AR).
  • No management team: three NEDs, no executives; KMP limited to directors (FY2026 AR).
  • Rising losses: FY2026 net loss up 184% to A$1.35m (FY2026 4E).
  • Declining non-dilutive income: other income fell from A$1.70m (FY2024) to A$0.19m (FY2026); UK R&D rebate stream ended with subsidiary dissolution.
  • Weak AD evidence: Exenatide showed no effect on phosphorylated Tau and an amyloid signal confounded by GAPDH changes (FY2026 AR).
  • Zero insider alignment: current directors hold nil shares or options (FY2026 AR).

Opportunities

  • Reverse takeover / asset injection: a listed shell with ~A$4m cash and ~900 holders is an efficient listing vehicle; the aborted Fragile X deal (Sep 2025) shows the Board's appetite.
  • IP divestment: BIO partnering profile indicates willingness to sell raised-ICP GLP-1RA IP for cash/equity.
  • Peptron ROFR / Asian licence: Peptron holds a first right of refusal over global IIH rights — a natural counterparty.
  • Class-based positioning: April 2026 program benchmarking Exenatide vs dulaglutide could support broader GLP-1RA-in-CNS IP.
  • TBI orphan pathway: EU ODD offers 10 years of market exclusivity and protocol assistance if a partner funds clinical work (FY2023 AR).
  • Interest income and tax losses: term deposits and A$2.7m of tax-effected losses enhance value to an acquirer that can satisfy loss-utilisation tests.

Threats

  • GLP-1RA commoditisation: the company itself concluded GLP-1RA pricing renders Presendin uneconomic in IIH (FY2024 AR).
  • Negative GLP-1 neuro readouts: Exenatide-PD3 (Parkinson's) and semaglutide evoke (AD) undermine the AD thesis (external).
  • Governance volatility: the Sep–Nov 2025 requisition cost an acquisition and drove legal fees to A$209k in FY2026 (FY2026 AR).
  • Cash erosion: cash plus deposits down from A$29.3m (FY2022) to A$4.0m (FY2026); continued burn without a transaction erodes shell value.
  • Concentrated register: top 20 hold 64.01%; Tattarang (11.77%) and Peterson/Celtic-associated holdings can determine outcomes.
  • Liquidity and delisting risk: thin trading (e.g., 5,000 shares traded on 6 Jul 2026), no broker coverage; ASX may scrutinise entities without a substantive business under Listing Rule 12.1.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
8 Apr 2025Q3 FY2025 quarterly: expanded Tessara collaboration under way, results expected 2H CY2025; review of neurological and non-neurological assetsSignals pipeline-diversification search
Aug 2025FY2025 Appendix 4E and Annual Report: net loss A$0.48m; cash A$5.38mLowest-ever loss
Exclusivity period, mid-2025 (dates not disclosed)Exclusive negotiations with a rare neurological disease company (Fragile X focus)Potential transformative transaction
Sep 2025Celtic Capital Pte Ltd serves requisition to remove Chair McAuliffe and ED DuthyGovernance contest
29 Sep 2025Director nominations for AGM announcedBoard contest
29–30 Sep 2025Corporate Update: exclusivity with Fragile X target discontinued, citing board instability; trading halt and reinstatement; response to ASX price and volume queryDeal collapse
8 Oct 2025Notice of General Meeting (requisitioned)Vote scheduled
17 Oct 2025Change in substantial holding lodgedRegister movement during contest
24 Oct 2025Notice of AGM (originally for 20 Nov 2025)AGM deferred
7 Nov 2025Resignation of Duthy, McAuliffe and Company Secretary; requisitioned meeting and AGM cancelled; trading pause and suspensionRequisitioner prevails without vote
10 Nov 2025Owen and Harding appointed NEDs; joint Company Secretaries appointed; office relocated to Perth CBD; reinstatement to quotationNew board
Oct 2025 – Jan 2026Q1 and Q2 FY2026 4Cs; Q2 admin costs A$444k (s249D and termination costs)Elevated governance costs
H1 FY2026EU orphan drug designation for Exenatide in TBI renewedIP/regulatory maintenance
16 Jan 2026Notice of AGM / Proxy Form—
22 Jan 2026Q2 FY2026 Appendix 4C—
12 Feb 2026Appendix 4D: H1 FY2026 net loss A$715,582 (+100.7% YoY); cash A$4.60m; BDO unqualified reviewLoss doubled on governance costs
17 Feb 2026AGM held; remuneration report carried (82.87%)Normalisation of governance
24 Feb 2026UK subsidiary dissolvedStructural simplification
23 Mar 2026Carla Healy resigns as joint Company Secretary—
24 Apr 2026Expanded preclinical program with Tessara announcedRenewed R&D activity
24 Apr 2026Q3 FY2026 4C: cash A$4.517m; operating outflow A$79kLow burn
Jun–Jul 2026Share price trades A$0.09–0.12 on thin volumeMarket cap ≈ A$7–9m
23 Jul 2026Q4 FY2026 4C: operating outflow A$501k (R&D A$379k); cash and deposits A$4.016mBurn rising with Tessara program
31 Aug 2026FY2026 Appendix 4E and Annual Report: net loss A$1.35m (+184%); BDO unqualified, no key audit mattersFull-year confirmation
31 Aug 2026Appendix 4G and Corporate Governance Statement (presumed lodged with annual report)—
Oct 2026 (expected)Q1 FY2027 Appendix 4C due by 31 Oct 2026; Notice of 2026 AGM expectedUpcoming disclosures

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Other revenue rose from AUD 0 Mn in FY2022 to AUD 0 Mn in FY2026.
Invex Therapeutics Ltd — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Other revenue00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Invex Therapeutics Ltd — Appendix 4E and Annual Report FY2026 (released 31 Aug 2026) (investorpa.com)
  2. Invex Therapeutics Ltd — Appendix 4E and Annual Report FY2024 (22 Aug 2024) (announcements.asx.com.au)
  3. Invex Therapeutics Ltd — Appendix 4E and Annual Report FY2023 (17 Aug 2023) (announcements.asx.com.au)
  4. Appendix 4D Half-Year Report, 31 Dec 2025 (bulletin.webull.com)
  5. Appendix 4D Half-Year Report, 31 Dec 2024 (announcements.asx.com.au)
  6. June 2026 Quarterly Activities Report and Appendix 4C (23 Jul 2026) (bulletin.webull.com)
  7. March 2026 Quarterly Activities Report (24 Apr 2026) (bulletin.webull.com)
  8. March 2025 Quarterly (8 Apr 2025) (wcsecure.weblink.com.au)
  9. September 2024 Quarterly (8 Oct 2024) (announcements.asx.com.au)
  10. Board and Officer Appointments and Company Address (10 Nov 2025) (bulletin.webull.com)
  11. Invex and Peptron Mutually Terminate Manufacturing Agreement (22 Dec 2023) (announcements.asx.com.au)
  12. ClinicalTrials.gov NCT05347147 (IIH EVOLVE) (clinicaltrials.gov)
  13. University of Birmingham — IPO release (5 Jul 2019) (birmingham.ac.uk)
  14. Biotech Daily, 22 May 2020 (Phase II results and A$26.2m placement) (biotechdaily.com.au)
  15. Smallcaps — A$26.2m placement (smallcaps.com.au)
  16. TipRanks — Celtic Capital requisition (tipranks.com)
  17. TipRanks — Negotiations halted (Sep 2025) (tipranks.com)
  18. InvestSMART announcements register (investsmart.com.au)
  19. Market Index — IXC profile and financials (marketindex.com.au)
  20. Motley Fool Australia — IXC price history (fool.com.au)
  21. Yahoo Finance — IXC.AX (fr.finance.yahoo.com)
  22. BIO International Convention partnering profile (convention.bio.org)
  23. Financial Filings — ISIN and filing index (financialfilings.com)
  24. roic.ai — company summary of 2025 developments (roic.ai)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.